|
 |
| home > pmps > autumn 2003 > temperature-controlled distribution of vaccines and high-value medicine |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
The cold chain encompasses all the storage and transport facilities necessary to ship a product requiring controlled low temperature storage from the manufacturer to the end user. Most biotechnology and pharmaceutical companies are structured globally and often have a complex supply chain. Pharmaceutical primary substances manufactured in one country are often shipped to a second country with a view to manufacturing bulk medicinal products.
This bulk medicinal product may be filled, labelled and packed in a final container in a third country from which it is shipped to the distributor, who may be situated in a fourth country. From the distributor, the medicinal product is sent to the end user, who may be located in a fifth country. When this complex supply chain must be temperature-controlled, the need for an effective and efficient cold chain becomes apparent. At every point in the cold chain, records have to be maintained to provide evidence of compliance with the labelled storage conditions.
At any given time of year, the distribution environment can vary greatly from country to country and even within the same country. The environment will also change significantly with the season. The International Committee on Harmonisation (ICH) has harmonised the stability testing requirements for medicinal products within three regions, namely Europe, Japan and the USA. Such harmonisation leads to harmonised labelling of storage conditions, which in turn leads to harmonised storage and shipping conditions. The advantage of such harmonisation lies in the fact that stability tests performed in one region are acceptable for the other two regions. Furthermore, medicinal products are treated in a consistent manner.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
19-20 January 2009, Copthorne Tara Hotel, London, UK
More info >>
|
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
|
